Tecentriq1200 mg/vial

Established (FDA-Approved) Indications

Tecentriq is a PD-L1 immune checkpoint inhibitor approved, alone or in combination with other anticancer agents, for the treatment of several malignancies under oncology specialist supervision:

• Non-small cell lung cancer (NSCLC): Metastatic NSCLC in combination with bevacizumab, paclitaxel, and carboplatin; metastatic non-squamous NSCLC in combination with nab-paclitaxel and carboplatin; metastatic NSCLC as a single agent following prior platinum-based chemotherapy or in first-line for tumors with high PD-L1 expression; adjuvant treatment after resection and platinum-based chemotherapy in stage II to IIIA NSCLC with PD-L1 expression on ≥1% of tumor cells.
• Small cell lung cancer (SCLC): First-line treatment of extensive-stage SCLC in combination with carboplatin and etoposide.
• Hepatocellular carcinoma (HCC): Unresectable or metastatic HCC in patients who have not received prior systemic therapy, in combination with bevacizumab.
• Melanoma: BRAF V600 mutation-positive unresectable or metastatic melanoma, in combination with cobimetinib and vemurafenib.
• Alveolar soft part sarcoma (ASPS): Unresectable or metastatic ASPS in adult and pediatric patients 2 years of age and older (approved under accelerated approval based on tumor response rate).

Note: Some earlier accelerated-approval indications of Tecentriq in urothelial carcinoma have since been withdrawn in certain markets following confirmatory trial results; use in that setting should follow current local regulatory and oncology guideline status.

All uses of Tecentriq require confirmation of diagnosis, staging, and (where specified) biomarker (PD-L1) testing, and must be initiated and monitored by a qualified oncology specialist.

Each single-dose vial contains Atezolizumab, a recombinant humanized monoclonal antibody directed against PD-L1, as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution for intravenous infusion after dilution. Common presentations include 840 mg/14 mL, 1200 mg/20 mL, and 1875 mg/15 mL (60 mg/mL) single-dose vials.

Tecentriq is an Fc-engineered, humanized immunoglobulin G1 (IgG1) monoclonal antibody that binds to programmed death-ligand 1 (PD-L1) and blocks its interaction with the PD-1 and B7.1 receptors. By interrupting this inhibitory signal, Tecentriq restores tumor-specific T-cell mediated immune responses, allowing the immune system to recognize and attack cancer cells more effectively.

Tecentriq is administered only as an intravenous infusion in a hospital or specialized oncology infusion setting, typically in combination with chemotherapy or other targeted agents depending on the cancer type and stage.

Antineoplastic agent; immune checkpoint inhibitor; anti-PD-L1 monoclonal antibody.

Mechanism of Action

Atezolizumab selectively binds PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, preventing PD-L1 from engaging PD-1 and B7.1 receptors on T-cells. This blockade removes an inhibitory checkpoint that tumors exploit to evade immune surveillance, thereby reactivating cytotoxic T-cell responses against malignant cells.

Pharmacokinetics

• Distribution: Steady-state volume of distribution approximately 6.9 L.
• Metabolism: Expected to be degraded into small peptides and amino acids via general protein catabolism pathways, not hepatic cytochrome P450 metabolism.
• Elimination half-life: Approximately 27 days; steady-state concentrations reached after about 6–9 weeks (2–3 cycles) of repeated dosing.
• Clearance: Not significantly affected by mild-to-moderate renal or hepatic impairment.

Tecentriq is administered only by intravenous infusion after dilution, through a dedicated infusion line, by trained healthcare professionals in a setting equipped to manage infusion and hypersensitivity reactions. It must never be given as an IV push or bolus injection.

Tecentriq is a monoclonal antibody and is not metabolized via cytochrome P450 enzymes, so classic pharmacokinetic drug-drug interactions are not expected.

• Systemic corticosteroids and immunosuppressants: Use before starting Tecentriq for reasons other than managing an immune-mediated adverse reaction may reduce its efficacy by dampening the immune response it depends on; avoid baseline immunosuppression unless clinically necessary.
• Live vaccines: Avoid administering live-attenuated vaccines during treatment with Tecentriq due to theoretical risk of enhanced immune-related effects and reduced vaccine safety data.

Common Side Effects

• Fatigue and asthenia
• Nausea and decreased appetite
• Cough and dyspnea
• Diarrhea
• Musculoskeletal pain
• Fever (pyrexia)
• Rash and pruritus
• Infection

Serious Side Effects

See Precautions and Warnings for full detail on immune-mediated adverse reactions (pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, skin reactions, and others) and infusion-related reactions associated with Tecentriq.

Pregnancy

Based on its mechanism of action, Tecentriq can cause fetal harm, as PD-1/PD-L1 signaling is important for maintaining immune tolerance during pregnancy. Tecentriq should be used during pregnancy only if the potential benefit clearly justifies the potential risk to the fetus, and only under specialist advice. Women of reproductive potential should use effective contraception during treatment with Tecentriq and for at least 5 months after the last dose.

Lactation

It is not known whether Tecentriq is excreted in human milk. Because of the potential for serious adverse reactions in breastfed infants, women are generally advised not to breastfeed during treatment with Tecentriq and for at least 5 months after the final dose; consult a physician before making feeding decisions.

Tecentriq carries no boxed warning under current labeling, but requires close specialist monitoring because of the following risks:

Immune-Mediated Adverse Reactions

Tecentriq can cause immune-mediated inflammation in virtually any organ system, including pneumonitis, colitis, hepatitis, endocrinopathies (hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, type 1 diabetes mellitus/diabetic ketoacidosis), nephritis, myocarditis, pancreatitis, and dermatologic reactions (including rare severe skin reactions). These reactions can occur at any time during or after treatment, may be severe or fatal, and require prompt recognition, laboratory/clinical monitoring, and management — often including corticosteroids and temporary or permanent discontinuation of Tecentriq depending on severity.

Infusion-Related Reactions

Monitor patients during and after infusion of Tecentriq, particularly during the first and second doses, for fever, chills, flushing, dyspnea, or hypotension; interrupt or slow the infusion for mild-to-moderate reactions and permanently discontinue for severe or life-threatening reactions.

Other Precautions

• Use with caution, and only after careful specialist risk-benefit assessment, in patients with significant active autoimmune disease, prior organ transplantation, or prior severe immune-related adverse reactions to another checkpoint inhibitor.
• Embryo-fetal toxicity — see Pregnancy and Lactation.
• Tecentriq must be prescribed and administered only under the supervision of a qualified oncology specialist in a facility able to manage severe immune-mediated and infusion reactions.

There is no established antidote or specific treatment for overdose of Tecentriq. In case of a suspected overdose, discontinue the infusion (if ongoing), closely monitor the patient for signs and symptoms of immune-mediated or infusion-related adverse reactions, and seek immediate medical attention. Management is supportive and symptomatic, guided by an oncology specialist; contact emergency medical services or a poison control center as appropriate.

Store Tecentriq vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze and do not shake. Keep out of reach of children. Diluted infusion solutions have limited stability and must be used within the timeframe specified by the manufacturer/pharmacy, stored as directed by the treating facility.

Renal Impairment

No dose adjustment of Tecentriq is required in patients with mild, moderate, or severe renal impairment based on available data.

Hepatic Impairment

No dose adjustment is required in patients with mild hepatic impairment. Data in moderate-to-severe hepatic impairment are limited; use with caution.

Elderly

No overall differences in safety or efficacy of Tecentriq have been reported between elderly and younger adult patients; no dose adjustment is required based on age alone.

Pediatric Use

See Pediatric Uses.

Treatment with Tecentriq is generally continued until disease progression, unacceptable toxicity, or (in some adjuvant regimens) completion of a defined treatment period (e.g., up to approximately 1 year in the adjuvant NSCLC setting). The exact duration is determined by the treating oncologist based on response, tolerability, and the specific approved regimen.

Monoclonal antibodies; immune checkpoint inhibitors (anti-PD-L1); antineoplastic agents.

Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 receptors on T-cells, releasing the brakes that tumors place on the immune system and restoring the ability of cytotoxic T-cells to recognize and destroy cancer cells.

Safety and efficacy of Tecentriq have not been established in the general pediatric population for most indications. The exception is unresectable or metastatic alveolar soft part sarcoma, where Tecentriq is approved for pediatric patients 2 years of age and older, dosed by body weight: 15 mg/kg IV every 3 weeks for patients weighing less than 38 kg, and the standard adult fixed dose for patients weighing 38 kg or more, up to a maximum of 1200 mg per dose. Use in children must be supervised by a pediatric oncology specialist.